phenelzine has been researched along with atenolol in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Campeas, R; Davies, S; Fyer, A; Gorman, J; Gully, R; Hatterer, J; Hollander, E; Liebowitz, MR; Papp, L; Schneier, F | 1 |
| Campeas, R; Fallon, BA; Feerick, J; Gitow, A; Hollander, E; Liebowitz, MR; Saoud, JB; Schneier, FR; Street, L; Welkowitz, LA | 1 |
| Campeas, R; Fyer, A; Gorman, J; Hatterer, J; Hollander, E; Liebowitz, MR; Papp, L; Schneier, F | 1 |
| Campeas, RB; Fyer, AJ; Gorman, JM; Hatterer, JA; Hollander, E; Liebowitz, MR; Papp, LA; Schneier, FR | 1 |
| Liebowitz, MR | 1 |
| Campeas, R; Fyer, AJ; Goetz, D; Gorman, JM; Hollander, E; Levin, AP; Liebowitz, MR; Papp, L; Sandberg, D | 1 |
| Campeas, R; Hollander, E; Levin, A; Liebowitz, MR; Papp, L; Sandberg, D | 1 |
| Merikangas, JR; Merikangas, KR | 1 |
1 review(s) available for phenelzine and atenolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 trial(s) available for phenelzine and atenolol
| Article | Year |
|---|---|
Phenelzine vs atenolol in social phobia. A placebo-controlled comparison.
Topics: Adolescent; Adult; Atenolol; Double-Blind Method; Female; Humans; Male; Middle Aged; Personality Inventory; Phenelzine; Phobic Disorders; Placebos; Prevalence; Psychiatric Status Rating Scales; Severity of Illness Index | 1992 |
Phenelzine and atenolol in social phobia.
Topics: Adolescent; Adult; Atenolol; Double-Blind Method; Female; Humans; Male; Phenelzine; Phobic Disorders; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Social Behavior | 1990 |
Pharmacotherapy of four men with paruresis.
Topics: Adult; Atenolol; Clinical Trials as Topic; Double-Blind Method; Humans; Male; Phenelzine; Phobic Disorders; Placebos; Urination Disorders | 1990 |
Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol.
Topics: Adult; Atenolol; Clinical Trials as Topic; Female; Humans; Male; Outcome and Process Assessment, Health Care; Phenelzine; Phobic Disorders; Placebos; Psychiatric Status Rating Scales; Random Allocation | 1988 |
Pharmacotherapy of social phobia. A condition distinct from panic attacks.
Topics: Adult; Atenolol; Clinical Trials as Topic; Humans; Male; Phenelzine; Phobic Disorders | 1987 |
Combination monoamine oxidase inhibitor and beta-blocker treatment of migraine, with anxiety and depression.
Topics: Adrenergic beta-Antagonists; Adult; Anxiety; Atenolol; Blood Pressure; Depressive Disorder; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Migraine Disorders; Monoamine Oxidase Inhibitors; Phenelzine; Treatment Outcome | 1995 |
8 other study(ies) available for phenelzine and atenolol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Treatment of social phobia with drugs other than benzodiazepines.
Topics: Adolescent; Atenolol; Benzamides; Buspirone; Child; Clinical Trials as Topic; Female; Fluoxetine; Humans; Male; Moclobemide; Phenelzine; Phobic Disorders; Placebos | 1991 |
Social phobia.
Topics: Adrenergic beta-Antagonists; Arousal; Atenolol; Behavior Therapy; Epinephrine; Humans; Interpersonal Relations; Panic; Phenelzine; Phobic Disorders; Social Environment | 1987 |